Toxic epidermal necrolysis, often called TEN, is a rare and life-threatening skin reaction in which large sheets of the outer skin layer die and peel away from the body, usually triggered by a medication. Mortality rates vary widely depending on severity, but the condition demands emergency-level care, typically in a burn unit. Though it shares features with severe burns, TEN is driven by the immune system turning against the body’s own skin cells, and that distinction shapes everything about how it is treated, who is most at risk, and what survivors face afterward.
What Triggers TEN
The overwhelming majority of TEN cases are caused by medications. Drug classes most frequently implicated include antibiotics, anticonvulsants (seizure medications), anti-cancer drugs, painkillers, and diuretics.
1PubMed Central. A Compilation of Drug Etiologies of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis A landmark study quantified the risk more precisely. Among drugs taken for short courses, sulfonamide antibiotics like trimethoprim-sulfamethoxazole carried the highest risk, with a relative risk around 172 compared to people not taking them. Aminopenicillins, quinolones, and cephalosporins also raised risk, though less dramatically. Among drugs taken for months or years, the danger was concentrated in the first two months of use. Carbamazepine, phenytoin, phenobarbital, valproic acid, allopurinol, and certain anti-inflammatory drugs all showed steeply elevated risk during that early window, with relative risks ranging from about 25 to 90.2PubMed. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
That two-month window matters practically. If you have been taking allopurinol for gout or carbamazepine for epilepsy for years without incident, your risk of TEN from that specific drug has already dropped substantially. The danger is highest when a susceptible person first starts the medication.
Drugs are not the only trigger. Infections can also cause TEN, though this is far less common. Mycoplasma pneumoniae (a bacterium that causes “walking pneumonia”) and herpes simplex virus are the most frequently documented infectious triggers.3Formosan Journal of Surgery. Toxic epidermal necrolysis secondary to Mycoplasma pneumoniae and herpes simplex virus infection Mycoplasma-triggered TEN appears to be especially relevant in children, where it may be the leading cause rather than medications.4International Journal of Research in Medical Sciences. A case of toxic epidermal necrolysis in a paediatric patient with mycoplasma pneumoniae infection In some cases no identifiable trigger is ever found, though these idiopathic cases are a small minority.
How the Immune System Destroys the Skin
TEN is not a chemical burn or a direct toxic effect of a drug on the skin. It is an immune-mediated catastrophe. The process begins when immune cells called cytotoxic T lymphocytes mistake skin cells for threats and launch a coordinated attack.5PubMed Central. Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions These T cells, along with natural killer-like cells found in the blisters, are fully functional killing machines.6PubMed Central. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors
The key weapon in this assault is a protein called granulysin. Gene expression studies found granulysin to be the most highly expressed cytotoxic molecule in TEN skin, present in blister fluid at concentrations hundreds to thousands of times higher than other cell-killing proteins like perforin or granzyme B. When researchers depleted granulysin from blister fluid in lab experiments, the fluid’s ability to kill skin cells dropped sharply.7PubMed. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis In plain terms, the immune system identifies the drug (or drug-modified protein) on the surface of skin cells, decides those cells are enemies, and then floods the area with a destructive protein that kills skin cells en masse. The result is widespread death of the epidermis.
What TEN Looks and Feels Like
TEN typically begins with flu-like symptoms: fever, malaise, sometimes a sore throat or burning eyes. Within days, a red, flat rash appears that quickly develops into blisters. These blisters enlarge and merge, and the skin becomes so fragile that gentle lateral pressure at the edge of a blister causes the surrounding normal-looking skin to slide off. This clinical sign, called Nikolsky’s sign, is a hallmark of TEN and helps clinicians identify the condition early.8PubMed Central. Nikolsky’s sign: A pathognomic boon
As the disease progresses, large sheets of epidermis separate from the underlying tissue and slough off, leaving raw, painful surfaces similar to a severe burn.9PubMed. Toxic epidermal necrolysis (Lyell’s disease) The mucous membranes are almost always involved: the lining of the mouth, the eyes, the genitals, and sometimes the respiratory and gastrointestinal tracts. This mucosal damage is part of what makes TEN so dangerous, contributing to pain, infection risk, and long-term complications.
A commonly cited threshold distinguishes TEN from the related condition Stevens-Johnson syndrome (SJS). When less than 10 percent of the body surface area is affected, the condition is classified as SJS. When more than 30 percent is involved, it is classified as TEN. Cases falling between 10 and 30 percent are labeled SJS/TEN overlap. These sit on a single spectrum of the same disease process, differing primarily in extent.
Telling TEN Apart from Conditions That Look Similar
Several other conditions can mimic TEN’s appearance, and misidentification delays life-saving treatment. Staphylococcal scalded skin syndrome (SSSS) is the most important mimic, especially in children. SSSS is caused by a bacterial toxin and also produces widespread skin peeling, but the mechanism is entirely different, the layer of separation is more superficial, and the treatment is antibiotics rather than immune suppression. SSSS can also resemble autoimmune blistering diseases such as pemphigus vulgaris and bullous pemphigoid, making rapid differentiation essential.10PubMed Central. Staphylococcal scalded skin syndrome: A rare mimicker of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults A skin biopsy, which reveals where in the skin the separation is occurring and what type of cell death is present, is usually the fastest way to confirm TEN and rule out its lookalikes.
Genetic Risk and HLA Testing
Not everyone who takes carbamazepine or allopurinol develops TEN. Genetic factors play a significant role in determining who is vulnerable, and the most important genetic markers identified so far are specific variants of HLA genes, which govern how immune cells recognize foreign molecules. The best-established link is between the HLA-B*15:02 allele and carbamazepine-induced SJS/TEN.11PubMed Central. HLA Association with Drug-Induced Adverse Reactions This allele is more common in people of Southeast Asian descent, and several countries now recommend or require HLA testing before prescribing carbamazepine to patients from these populations.
The picture is less clear in other ethnic groups and with other drugs. A review of studies in Asian Indian populations found HLA associations with several drugs that trigger SJS/TEN, including anti-epileptic drugs and anti-inflammatory medications, but the studies involved small numbers of patients. The evidence is not yet strong enough to confidently extend these associations to broader populations of the same ethnicity.12PubMed Central. Genetic Markers for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in the Asian Indian Population: Implications on Prevention
Despite these limitations, the trajectory of the field is toward broader preemptive genetic testing. For drugs like carbamazepine and lamotrigine, HLA testing before the first prescription can identify high-risk individuals and allow clinicians to choose alternative medications or adjust doses.13PubMed. Pharmacogenetic biomarkers associated with risk of developing severe drug eruptions and clinical implementation of HLA genetic testing The practical challenge is that testing infrastructure, insurance coverage, and physician awareness remain uneven across healthcare systems worldwide.
Predicting How Severe a Case Will Be
Once TEN is diagnosed, clinicians use a scoring system called SCORTEN to estimate the risk of death. SCORTEN tallies seven independent risk factors: age over 40, the presence of cancer, a heart rate above 120, initial skin detachment covering more than 10 percent of the body, and three blood chemistry values (elevated urea, elevated glucose, and low bicarbonate). Each factor present adds a point, and the odds of death roughly triple with each additional point.14PubMed. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis
SCORTEN is the most widely used prognostic tool, but its accuracy has been debated. A systematic review and meta-analysis found that overall, SCORTEN performs reasonably well as a mortality predictor. However, it tends to underestimate mortality for patients with scores of 3 or below and overestimate it for those scoring above 3. The score’s accuracy has also shifted over time, with more recent years showing a progressive drop in observed deaths relative to what SCORTEN predicts, possibly reflecting improvements in burn-unit care.15PubMed. Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis A separate single-center analysis illustrated this gap starkly, finding SCORTEN estimated a death rate of about 42 percent while the actual death rate in their cohort was 12.5 percent.16PubMed Central. Accuracy of SCORTEN in predicting mortality in toxic epidermal necrolysis The tool remains useful for guiding treatment intensity and communicating prognosis to families, but clinicians are increasingly aware that it may paint an overly bleak picture at some severity levels.
Treatment in the Acute Phase
The first and most important step is identifying and immediately stopping the offending drug. Every hour that a culprit medication continues to circulate worsens the immune response. After withdrawal, care is primarily supportive: fluid replacement, wound management, pain control, nutritional support, and infection prevention. Because the skin barrier is lost over large areas, the physiological challenges closely parallel those of major burns, and patients are typically transferred to a burn intensive care unit.
A survey of burn centers across the United States found that while every center provided this core supportive care, there was little standardization beyond that. Approaches to wound dressings, antibiotic use, and especially immune-modulating therapies varied substantially from center to center.17PubMed. Burn unit care of Stevens Johnson syndrome/toxic epidermal necrolysis: A survey
That lack of consensus extends to systemic treatments aimed at halting the immune attack. Several immune-modulating therapies have been tried, including systemic corticosteroids, intravenous immunoglobulin (IVIg), cyclosporine, and anti-TNF biologics like etanercept. Results have been inconsistent across studies, and the use of corticosteroids and IVIg remains particularly controversial.18PubMed Central. A Review of the Systemic Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis A network meta-analysis found that combining corticosteroids with IVIg may reduce mortality in patients with SJS/TEN overlap and TEN, and that cyclosporine and etanercept show promise but need more evidence.19Journal of the American Academy of Dermatology. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis The honest assessment is that no single immunotherapy has proven itself in large, well-controlled trials, and treatment decisions still rely heavily on clinical judgment and institutional experience.
Life After TEN
Surviving the acute phase of TEN is only part of the story. A study of over 120 TEN survivors found that long-term physical problems were the rule rather than the exception. Roughly 84 percent reported ongoing skin problems such as scarring, pigmentation changes, and abnormal nail growth. About 60 percent had chronic eye problems, and about half experienced persistent issues with their oral mucous membranes.20PubMed Central. Long-term Physical and Psychological Outcomes of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
The psychological toll was equally striking. In the same study, more than half of survivors showed signs of depression, over 40 percent showed signs of anxiety, and about one in five screened positive for post-traumatic stress disorder.21PubMed Central. Long-term Physical and Psychological Outcomes of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis These findings underscore that TEN is not an event that ends at hospital discharge. Survivors often need ongoing dermatological, ophthalmological, and psychological follow-up for years.
Among the long-term complications, eye damage deserves special attention because early intervention can dramatically change outcomes. Ocular involvement in TEN can progress from acute inflammation to chronic scarring of the eyelids, the eye surface, and the tissue folds that connect the eyelid to the eyeball. Left untreated, this scarring process leads to severe dry eyes, light sensitivity, corneal damage, and in the worst cases, vision loss.22PubMed Central. Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis Amniotic membrane transplantation, in which preserved tissue from the innermost layer of the placenta is applied to the eye surface, has emerged as a way to suppress inflammation and support healing during the acute phase. A systematic review found that when amniotic membrane transplantation was performed early, ideally within two weeks of symptom onset, most patients achieved corrected visual acuity of 20/50 or better, with low rates of chronic eye complications.23PubMed. Ocular outcomes of amniotic membrane transplantation in acute and chronic Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review The window matters: the sooner this intervention is deployed, the better the long-term visual outcome.
How TEN Differs in Children
Children with TEN tend to have a different profile than adults in several important ways. A comparison study found that children were more likely to have milder disease on the spectrum (SJS rather than full TEN), while adults were more likely to present with extensive skin involvement. The triggering cause also diverged sharply: anticonvulsant drugs were the leading trigger in adults (about 65 percent of cases), while Mycoplasma pneumoniae infection was the most common trigger in children (about 42 percent). Mucosal involvement occurred at similar rates in both groups, but the severity of that involvement, systemic complications, secondary infections, and hospital stays were all significantly worse in adults. The most dramatic difference was in mortality: no deaths were observed among the pediatric patients in the study, compared with 26 percent mortality in the adult group.24European Journal of Pediatric Dermatology. Stevens-Johnson syndrome and toxic epidermal necrolysis. A comparison of outcomes between adults and children
This does not mean TEN in children is benign. Pediatric patients still face painful hospitalizations, potential eye damage, and long-term scarring. The fact that infections rather than drugs are more often the trigger in children also means the prevention strategy differs. In adults, avoiding high-risk drugs or screening with HLA testing offers a realistic path to prevention. In children, TEN may arrive without warning alongside a common respiratory infection, making it harder to anticipate.
The Cost and Burden of Care
TEN is expensive to treat, in large part because burn-unit stays are among the most resource-intensive forms of hospital care. A study from Korea found that the median inpatient cost for TEN patients was roughly $8,000 per person, with individual cases ranging from about $1,100 to over $52,000. Each additional hospital day added about $180 to the bill, and patients who died incurred an additional $14,000 or more in costs compared to survivors, reflecting the intensive interventions attempted in end-stage cases.25PubMed Central. Direct costs of severe cutaneous adverse reactions in a tertiary hospital in Korea A separate analysis from Thailand similarly found that healthcare utilization and cost for SJS/TEN were substantial, reinforcing the economic argument for prevention through strategies like genetic screening.26PubMed Central. Healthcare utilization and cost of Stevens-Johnson syndrome and toxic epidermal necrolysis management in Thailand These figures capture only the acute hospitalization. They do not include follow-up ophthalmology visits, skin care, mental health treatment, or lost productivity, all of which survivors frequently require for years.
Pharmacovigilance and Regulatory Action
Because TEN is rare, no single hospital accumulates enough cases to spot emerging drug-related patterns on its own. Large adverse-event databases maintained by regulatory agencies are the primary surveillance tool. A 55-year retrospective analysis of the FDA’s adverse-event reporting system highlighted antiepileptics, analgesics, and antibacterials as the drug classes most consistently flagged for SJS/TEN reports, reinforcing what clinical studies have found.27PubMed Central. Pharmacovigilance and Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN): 55 Years of Retrospective Analysis of the FDA Adverse Event Reporting System (FAERS) Database
These database signals translate into concrete regulatory action. Since 2016, the FDA has issued drug safety-related labeling changes for nine medications due to their link with SJS/TEN and related severe skin reactions. The list includes lamotrigine, allopurinol, phenytoin, carbamazepine, amoxicillin, trimethoprim-sulfamethoxazole, rifampin, levetiracetam, and vancomycin. Four of those drugs — allopurinol, phenytoin, rifampin, and trimethoprim-sulfamethoxazole — have each undergone multiple label revisions, reflecting both the strength of the safety signal and possibly the influence of updated labeling on subsequent reporting patterns.28PubMed Central. Demographics, Overlap, and Latency of Severe Cutaneous Adverse Reactions in an FDA Database For patients, the practical takeaway is that drug labels now carry more explicit warnings about TEN risk than they did a decade ago, and pharmacists and physicians have clearer guidance on when to discuss the risk before starting a new prescription.